The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions
- PMID: 10586385
- DOI: 10.1177/00912709922012006
The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions
Abstract
P-glycoprotein (PGP) is well known because of its contribution to multiple-drug resistance during anticancer treatment. More recent work indicates that PGP mediates the transcellular transport of many drugs in addition to anticancer compounds. Because of this reason, its potential role in clinically significant drug-drug interactions has just begun to be realized. This article provides an overview of published in vitro, in situ, and in vivo drug-drug interaction results that are related to PGP transport so that the awareness of the scientific community can be heightened. In addition, several recommendations are made to take full advantage of the recently published data.
Similar articles
-
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.Mol Carcinog. 1995 Jul;13(3):129-34. doi: 10.1002/mc.2940130302. Mol Carcinog. 1995. PMID: 7619215 Review. No abstract available.
-
P-Glycoprotein in clinical cardiology.Circulation. 1999 Feb 2;99(4):472-4. doi: 10.1161/01.cir.99.4.472. Circulation. 1999. PMID: 9927391 No abstract available.
-
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. doi: 10.1124/jpet.102.037549. J Pharmacol Exp Ther. 2002. PMID: 12235267
-
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.Pharm Res. 1999 Mar;16(3):408-14. doi: 10.1023/a:1018877803319. Pharm Res. 1999. PMID: 10213372
-
Transport proteins and intestinal metabolism: P-glycoprotein and cytochrome P4503A.Ther Drug Monit. 2004 Apr;26(2):104-6. doi: 10.1097/00007691-200404000-00002. Ther Drug Monit. 2004. PMID: 15228147 Review.
Cited by
-
Manufacturer's drug interaction and postmarketing adverse event data: what are appropriate uses?Drug Saf. 2001;24(9):637-43. doi: 10.2165/00002018-200124090-00001. Drug Saf. 2001. PMID: 11522118 Review.
-
Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1.Pharm Res. 2006 Jul;23(7):1460-72. doi: 10.1007/s11095-006-0285-7. Epub 2006 Jun 21. Pharm Res. 2006. PMID: 16779700
-
Pulchinenosides from Pulsatilla Chinensis Increase P-Glycoprotein Activity and Induce P-Glycoprotein Expression.Evid Based Complement Alternat Med. 2020 Feb 18;2020:4861719. doi: 10.1155/2020/4861719. eCollection 2020. Evid Based Complement Alternat Med. 2020. PMID: 32148543 Free PMC article.
-
Safety and efficacy of statins in Asians.Am J Cardiol. 2007 Feb 1;99(3):410-4. doi: 10.1016/j.amjcard.2006.08.051. Epub 2006 Dec 15. Am J Cardiol. 2007. PMID: 17261409 Free PMC article. Review.
-
Plant Metabolites as Potential Agents That Potentiate or Block Resistance Mechanisms Involving β-Lactamases and Efflux Pumps.Int J Mol Sci. 2025 Jun 10;26(12):5550. doi: 10.3390/ijms26125550. Int J Mol Sci. 2025. PMID: 40565013 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous